GRCE
Grace Therapeutics Inc
NASDAQ · Pharmaceuticals
$3.60
+0.12 (+3.45%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.56M | 18.44M | 15.17M |
| Net Income | 2.85M | 2.16M | 2.15M |
| EPS | — | — | — |
| Profit Margin | 14.6% | 11.7% | 14.2% |
| Rev Growth | +16.3% | +19.0% | +18.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 10.36M | 10.33M | 10.78M |
| Total Equity | 20.75M | 18.28M | 18.26M |
| D/E Ratio | 0.50 | 0.57 | 0.59 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 5.50M | 5.11M | 4.77M |
| Free Cash Flow | 2.45M | 3.17M | 1.86M |